1. Pink Sheet
  2. >>Geography
  3. >>Europe
  4. >>United Kingdom

UK To Have Own Conditional Drug Approval Scheme in 2021

Companies Must Register To Make Submissions

 
• By Ian Schofield

New UK guidance on the post-Brexit regulation of medicines says the Medicines and Healthcare products Regulatory Agency will be able to issue its own conditional marketing authorizations next year. The agency has also outlined how drug safety reports should be submitted.

Brexit
The UK will take over responsibility for conditional approvals next year • Source: Shutterstock

The UK government has confirmed that mechanisms will be in place from 1 January 2021 allowing the medicines regulator, the MHRA, to issue national conditional marketing authorizations (CMAs) and to approve products under exceptional circumstances, based on the same eligibility criteria as the existing EU schemes.

The UK is having to change its regulations because when the Brexit transition period ends on 31 December, the MHRA...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United Kingdom

Canada, Britain And Australia Push For Greater International Regulatory Alignment

 
• By Eliza Slawther

Canada’s drug regulator is using amended drug laws to increase the use of regulatory reliance pathways to improve efficiency and support international alignment, while the UK’s MHRA has held talks with Australia’s TGA on topics including the role of AI in regulatory frameworks.

UK Cell And Gene Therapy Group Calls For AMR-Style Innovative Payment Pilot

 
• By Francesca Bruce

The UK can look to other countries including Denmark, Spain and Canada for tips on how to make sure it is a competitive market for cell and gene therapies, according to the Cell and Gene Therapy Collective.

Clawbacks And Clinical Trial Set Up Are Among UK’s Investment Deterrents

 
• By Francesca Bruce

In the wake of MSD’s decision not to invest $1.35bn in the UK, the Association of the British Pharmaceutical Industry has set out the county’s comparative strengths and weaknesses.

Merck & Co. Withdrawal Seen As Warning Of UK’s Declining Attractiveness

 
• By Andrew McConaghie

The decision to terminate discovery research was influenced by the US company’s cost-cutting measures but also discontent over the UK’s punitive clawback of revenues.

More from Europe

Canada, Britain And Australia Push For Greater International Regulatory Alignment

 
• By Eliza Slawther

Canada’s drug regulator is using amended drug laws to increase the use of regulatory reliance pathways to improve efficiency and support international alignment, while the UK’s MHRA has held talks with Australia’s TGA on topics including the role of AI in regulatory frameworks.

Sanofi’s Rilzabrutinib & Belumosudil Among Seven Drugs Facing EMA Oral Explanations

 
• By Vibha Sharma

The sponsors of seven new medicines nearing the end of their EU regulatory review are due – or possibly due – to appear before the European Medicines Agency’s human medicines committee, the CHMP, to address remaining concerns about their marketing applications.

EU’s Draft GMP Guideline Signals Major Cultural Shift In Pharma Quality Compliance

 
• By Vibha Sharma

While the EU's draft good manufacturing practice guideline on pharmaceutical quality systems reflects modern quality management principles, it also presents significant operational and resource challenges for drug companies.